Amstruprafn9040
To evaluate the clinical utility of quantitative values obtained with bone single photon emission computed tomography/computed tomography (SPECT/CT) for primary bone neoplasms.
Bone SPECT/CT scans of 23 patients with 19 benign bone neoplasms (5 osteoid osteomas, 4 bone giant cell tumor, 4 osteofibrous dysplasia, 3 intraosseous ganglion, 2 aneurysmal bone cyst, 1 intraosseous hemangioma) and 5 malignant bone neoplasms (2 osteosarcoma, 1 periosteal osteosarcoma, 1 malignancy in bone giant cell tumor, 1 Ewing sarcoma) were retrospectively analyzed with maximum standardized uptake value (SUVmax), peak SUV (SUVpeak), mean SUV (SUVmean), metabolic bone volume (MBV), and total bone uptake (TBU) of primary lesions.
Mean SUVmax of 19 benign and 5 malignant primary bone neoplasms were 6.89±3.26 (range 3.9-15.13) and 10.31±3.19 (5.0-13.45) respectively, with statistically significant difference (P=0.048). Mean SUVpeak of those were 5.87±2.83 (range 3.5-13.63) and 9.18±3.05 (4.09-12.03) respectively, with statistically significant difference (P=0.032). Mean SUVmean of those were 4.43±2.11 (range 2.59-9.37) and 7.13±2.90 (3.3-10.42) respectively, with statistically significant difference (P=0.027). Mean MBV of those were 22.0±30.0 (range 2.47-110.61) and 27.8±39.94 (8.59-99.24) respectively, with no statistically significant difference (P=0.72). Mean TBU of those were 80.64±94.57 (range 10.50-373.57) and 166.60±203.97 (28.68-528.13) respectively, with no statistically significant difference (P=0.17).
Quantitative values obtained with bone SPECT/CT may serve as osteoblastic biomarkers for primary bone neoplasm.
Quantitative values obtained with bone SPECT/CT may serve as osteoblastic biomarkers for primary bone neoplasm.
In this study, we aimed to evaluate the concordance of biochemical treatment response with gallium-68-prostate specific membrane antigen (
Ga-PSMA) positron emission tomography/computed tomography (PET/CT) treatment response in prostate cancer (PCa) and investigate their prognostic effects on survival.
One hundred and fifty-onepatients with PCa, who underwent
Ga-PSMA PET/CT imaging in our clinic between May 2016 and December 2019, were on treatment, and had pre-treatment and post-treatment imaging studies were included in our study. The treatment patients received and prostate-specific antigen (PSA) levels at the time of PET/CT imaging were recorded. Pre- and post-treatment whole-body metabolic tumor volume (MTVw), whole-body total lesion PSMA (TLPw), percent change in PSA (ΔPSA), ΔMTV, and ΔTLP values were calculated in all patients. Survival time of all patients was measured from the time of initial PET imaging.
Median age of patients included in our study was 71 years (range 51-88). When ΔPSA resp valuable imaging technique for diagnostic purposes as well as follow-up and prognostic evaluation.
We observed that biochemical response and whole-body volumetric 68Ga-PSMA PET/CT parameter response showed correlation and concordance in all groups with PCa, which was more significant when PSA level was ≥10ng/mL. MTVw1 and ΔMTV parameters obtained via 68Ga-PSMA PET/CT were independent prognostic factors for mortality in PCa. Gallium-68-PSMA PET/CT is a valuable imaging technique for diagnostic purposes as well as follow-up and prognostic evaluation.
To determine the risk group of patients with locally advanced squamous cell carcinoma of the uterine cervix that will resist to treatment before concomitant chemoradiotherapy and who will develop metastasis via fluorine-18-fluorodeoxyglucose (
F-FDG) positron emission tomography/computed tomography (PET/CT) metabolic data.
Fifty two patients with carcinoma of the uterine cervix who were treated in our clinic between 2015-2018 were evaluated. The presence of human papilloma virus (HPV) from the first paraffin blocks diagnosed in all patients has been tested withreal time polymerase chain reaction (PCR). All patients received brachytherapy after concomittant chemotherapy with external radiotherapy. The first
F-FDG PET/CT and magnetic resonance images (MRI) images obtained for pretreatment staging and MRI after external radiotherapy were retrospectively reviewed. The patients who resisted concomittant chemoradiotherapy were tried and determined with pre-treatment
F-FDG PET/CT metabolic data.
The folloould not predict the resistant patients to treatment of primary tumor.
We investigated whether heat shock protein 90α (HSP90α) expression is associated with fluorine-18-labeled fluoro-2-deoxy-D-glucose (
F-FDG) uptake and whether
F-FDG positron emission tomography/computed tomography (PET/CT) can be used to predict the status of HSP90α expression in colorectal cancer (CRC).
The medical records and preoperative
F-FDG PET/CT studies of 51 patients with newly diagnosed CRC who underwent surgical treatment were retrospectively reviewed. The maximum standardized uptake value (SUVmax) of the primary tumor was calculated from the level of
F-FDG uptake. HSP90α expression was determined by immunohistochemistry. The relationship between SUVmax and HSP90α expression was analyzed.
Colorectal cancer with high HSP90α expression had significantly higher SUVmax than CRC with low HSP90α expression (18.88±10.06 vs. 12.38±5.04, P=0.003). There was a significant correlation between HSP90α expression and
F-FDG uptake (r=0.354, P=0.011). The highest accuracy for determining HSP90α status (68.6%) was obtained with a SUVmax cut-off of 15.4. Maximum SUV was the only predictor of HSP90α expression on multivariate logistic regression analysis (Odds Ratio=5.384, P=0.016).
The expression status of HSP90α was significantly related to
F-FDG uptake in CRC.
The expression status of HSP90α was significantly related to 18F-FDG uptake in CRC.
The correlation between the computer-assisted bone scan index (BSI) responses versus clinical response classification if bone metastases in prostate cancer patients are not clear. We compared changes in BSI with Prostate Cancer Working Group-3 (PCWG3) and MD Anderson (MDA) criteria.
Fifty-six consecutive patients with at least two bone scans (BS) within 12 months were included, who had BS before and after treatment with the same anticancer agent.
Progressive disease (PD) by PCWG3 criteria was seen in 28% of the cases (median BSI increased by 1.69 units) versus non-PD in 72% (BSI change -0.13). learn more MDAnderson showed PD in 34% (BSI increase 0.49), 45% stable disease (BSI change 0.00), and 20% partial responses (BSI decrease 1.44). Absolute BSI changes differed significantly among response categories by PCWG3 and MDA criteria (both P<0.0001). Response classification using dichotomized BSI data (>0/≤0 and >0.3/≤0.3 BSI units) showed a significant correlation with PCWG3 and MDA criteria (all P<0.001).
